Allergan is just the latest in a flurry of strategic acquisitions that has boosted Actavis’ (ACT) size, drug portfolio and global reach at a rapid pace. The stock has found support at its 50-day moving average as it shapes a flat base with a potential buy point at 317.82 (see today’s Investor’s Corner column on Page B4 for more on the 50-day line).